Gelonghui, May 9丨Pharmaceutical Stone Technology (300725.SZ) said on the investor interactive platform that our products and services are mainly used in pharmaceutical companies' new drug research and development projects. Judging from the global innovative drug development pattern, overseas companies dominate, so the company's revenue mainly comes from overseas. In 2023, revenue from foreign customers accounted for 68.48%.
药石科技(300725.SZ)：2023年度来自于国外客户的收入占比68.48%
Pharmaceutical Stone Technology (300725.SZ): Revenue from foreign customers accounted for 68.48% in 2023
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.